CMPS

COMPASS Pathways Plc (CMPS) - 10-Q Summary for Period Ended September 30, 2025

Business Context and Reporting Period

COMPASS Pathways Plc is a clinical-stage biotechnology company developing COMP360, a psilocybin-based treatment for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). The company is incorporated in England and Wales and trades on the Nasdaq Global Select Market. This report covers the quarterly period ended September 30, 2025. The company has not generated any revenue to date and relies on capital raised through equity offerings, debt financing, and tax credits to fund operations.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The significant increase in net loss for Q3 2025 is primarily driven by a non-cash fair value adjustment of warrant liabilities.

Material Changes vs. Prior Period

• Net Loss Expansion: Net loss for the three months ended September 30, 2025, increased to $137.7 million from $38.5 million in the same period in 2024. This is largely attributable to a $101.3 million non-cash loss from the fair value change of warrant liabilities issued in the January 2025 financing.
• Operating Expenses: Total operating expenses decreased by $7.4 million in Q3 2025 compared to Q3 2024, driven by reduced development expenses following the termination of discovery programs and lower personnel costs due to a workforce reorganization in late 2024.
• Liquidity Position: Cash and cash equivalents increased to $185.9 million as of September 30, 2025, up from $165.1 million at year-end 2024, following the January 2025 financing which raised approximately $149.8 million in gross proceeds.
• Warrant Liability: A new warrant liability of $165.6 million was recorded on the balance sheet as of September 30, 2025, related to the 2025 Financing. This liability did not exist in the prior year period.

Guidance, Outlook, and Management Commentary

• Clinical Progress: In June 2025, the company reported that its first pivotal Phase 3 trial (COMP005) for TRD achieved its primary endpoint with a p-value of <0.001. The second pivotal trial (COMP006) has completed enrollment. The company plans to disclose primary endpoint data from COMP006 in Q1 2026 and is preparing for a rolling New Drug Application (NDA) submission to the FDA.
• Cash Runway: Management believes the $185.9 million in cash on hand is sufficient to fund operating expenses and capital expenditures into 2027. This estimate excludes potential proceeds from the exercise of outstanding warrants.
• Financing Milestones: The company issued 2025 ADS Warrants with an exercise price of $5.7960. These warrants become exercisable following a specified data milestone. If the ADS price exceeds the exercise price for three consecutive trading days, the company may force cash exercise, potentially raising an additional $203.2 million. However, this is not included in the current cash runway estimate.
• Regulatory Risks: The filing highlights risks related to a U.S. federal government shutdown (effective September 30, 2025), which has led to furloughs at the FDA and SEC, potentially delaying regulatory reviews and interactions. Additionally, the company faces risks regarding the rescheduling of psilocybin from Schedule I to a lower schedule by the DEA, which is required for commercial marketing in the U.S.

Investor Verification Checklist

• Warrant Liability Volatility: Verify the impact of the $165.6 million warrant liability on future earnings, as fair value adjustments will cause significant fluctuations in reported net loss regardless of operational performance.
• Cash Burn Rate: Confirm the sustainability of the "into 2027" cash runway given the high operating costs of Phase 3 trials and the potential for increased commercialization spending.
• Regulatory Timeline: Monitor the status of the U.S. government shutdown and its specific impact on FDA review timelines for the planned rolling NDA submission.
• Debt Covenants: Review compliance with the Hercules Loan Agreement, specifically the minimum cash covenant of $22.5 million, which is currently met but requires ongoing monitoring.
• Warrant Exercise Conditions: Track the trading price of ADSs relative to the $5.7960 exercise price of the 2025 Warrants to assess the likelihood of forced cash exercise and potential dilution.